Member Profile

Since its establishment in 1999, the BIONET Group has grown to include three subsidiaries specializing in regenerative medicine/cell therapy, precision medicine/ genetic medicine and digital healthcare/scientific informatics: BIONET Corp., GGA Corp., and BIONET Therapeutics Corp. BIONET Therapeutics, newly established in 2022 to maximize the Group’s synergies, is dedicated to accelerate the development of various regenerative medicine treatments and new cell therapies.

Our cutting-edge products and technologies, including stem cells, exosomes, genetic testing, and skin care products, have benefited over 1.6 million people across 17 countries, serving over 50% of newborns and 95.5% of reproductive medicine centers in Taiwan. The BIONET group is collaborating with over 500 medical institutions worldwide and remains committed to pushing the boundaries of regenerative medicine, precision health, and digital medicine to lead the industry and enhance the quality of life for people around the world.

To date, BIONET received several cell therapy approvals from the Ministry of Health and Welfare under the special management regulation , including adipose-derived mesenchymal stem cell treatment for degenerative arthritis, knee cartilage defects, chronic wounds, subcutaneous and soft tissue defects ,and immune cell (CIK) treatment of colorectal cancer, lung cancer, breast cancer, liver cancer and other cancers. Furthermore, BIONET also expand the application scope of regenerative medicine and cell therapy, medical and skin care products/hair growth development, cell derivatives such as Exosomes, and cell processing. In 2022, BIONET Group established new company “BIONET Therapeutics Corp.” which combines smart research and development, gene and cell therapy development technology, and digital simulation innovation capabilities to provide broader services.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2005 The mesenchymal stem cell bank was established, which has core technology and manufacturing capabilities for the medical-grade cell therapy products. With the “Hybrid Model” combining the advantages of private banking and public donation, BIONET assisted Chinese people at home and abroad to match medical cord blood transplants.
   2011 BIONET is the first private cord blood bank in Asia to be accredited by the American Association of Blood Banks (AABB). Moreover, BIONET is the first company in the world to receive accreditations in three categories from AABB, including Cord Blood (CB), Somatic cell and Hematopoietic progenitor cells (HPC), and Mesenchymal Stem Cells (MSC). So far, it has 8 times of certification by AABB.
   2014 BIONET stepped into the aesthetic medicine market by developing advanced skin care technology to promote the application of Stem Cell technology and share the benefits with the public, also launched RE. O series skin care products. BIONET built a GMP facility in Southern Taiwan Science Park to offer OEM services to domestic and foreign markets.
   2017 BIONET was cooperated with medical center to initiate the clinical trial about “MSC to treat severe lung injury, pneumonia, and sepsis with acute respiratory distress syndrome (ARDS) caused by influenza, and other virus”. This study was recently published in the international critical care journal “Critical Care Medicine”.
   2020 The “Autologous adipose-derived stem cell transplantation over 6 weeks chronic ulcer or chronic wounds project” was approved by the Ministry of Health and Welfare. “Special Administrative Measures” was approved to treat “stage 4 solid cancer” through “autoimmune cells”.
   2020 Approved for Compassionate Use, and cooperated with many large medical centers to assist in the treatment of acute respiratory distress syndrome (ARDS) caused by infection with covid-19; BIONET’s Mesenchymal Stem Cell Bank has sufficient cells to produce units for domestic and foreign medical use.
   2021 BIONET has invested in respiratory-related disease research more than 15 years, and was approved by Ministry of Health and Welfare for the treatment of acute respiratory distress syndrome (ARDS) phase II human clinical trials with the medical center.
   2022 BIONET Group established new company “BIONET Therapeutics Corp.” specializing in the development of regenerative medicine and cell therapy products for wider services.